Unknown

Dataset Information

0

Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small-cell lung cancer cells.


ABSTRACT: ABT-263 (Navitoclax) is a BH3-mimetic drugs targeting anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, thereby inducing apoptosis. In small-cell lung cancer (SCLC) cells, the response to ABT-263 is associated with the expression of myeloid cell leukemia-1 (MCL-1) protein, however the efficacy of ABT-263 in non-small-cell lung cancer (NSCLC) has not been thoroughly evaluated. There are currently no established biomarkers for predicting the efficacy of ABT-263 treatment in NSCLC. We screened a panel of different NSCLC cell lines and found that ABT-263 inhibited cell proliferation and induced apoptosis in Calu-1, Calu-3, and BID007 cells. Inconsistent with previous reports on SCLC, low levels of MCL-1 did not predict the response to ABT-263 in NSCLC cells, however we found that intracellular levels of reactive oxygen species (ROS) in cancer cells were associated with sensitivity to ABT-263 in NSCLC cells. We also showed that increasing the level of intracellular ROS could enhance the sensitivity to ABT-263 in NSCLC cells. In summary, we propose that the intracellular levels of ROS could be used as a potential novel biomarker for predicting a response to ABT-263 in NSCLC. Furthermore, we show some evidence supporting the further assessment of ABT-263 as a new therapeutic strategy in patients with NSCLC combined with agents regulating ROS levels. We believe that our findings and follow-up studies on this matter would lead to novel diagnostic and treatment strategies in patients with NSCLC.

SUBMITTER: Ohgino K 

PROVIDER: S-EPMC7541018 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small-cell lung cancer cells.

Ohgino Keiko K   Terai Hideki H   Yasuda Hiroyuki H   Nukaga Shigenari S   Hamamoto Junko J   Tani Tetsuo T   Kuroda Aoi A   Arai Daisuke D   Ishioka Kota K   Masuzawa Keita K   Ikemura Shinnosuke S   Kawada Ichiro I   Naoki Katsuhiko K   Fukunaga Koichi K   Soejima Kenzo K  

Cancer science 20200805 10


ABT-263 (Navitoclax) is a BH3-mimetic drugs targeting anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, thereby inducing apoptosis. In small-cell lung cancer (SCLC) cells, the response to ABT-263 is associated with the expression of myeloid cell leukemia-1 (MCL-1) protein, however the efficacy of ABT-263 in non-small-cell lung cancer (NSCLC) has not been thoroughly evaluated. There are currently no established biomarkers for predicting the efficacy of  ...[more]

Similar Datasets

| S-EPMC2892288 | biostudies-literature
| S-EPMC3527691 | biostudies-literature
| S-EPMC5288152 | biostudies-literature
| S-EPMC2910502 | biostudies-literature
| S-EPMC2921948 | biostudies-literature
| S-EPMC6047776 | biostudies-literature
| S-EPMC7877005 | biostudies-literature
| S-EPMC5688167 | biostudies-literature
| S-EPMC4847809 | biostudies-literature
| S-EPMC8750417 | biostudies-literature